Cyclosporine in dermatology

Journal of the American Academy of Dermatology

Volumn 21, Issue 6, 1989, Pages 1245-1256

  Gupta, Aditya K ^a   Brown, Marc D ^a   Ellis, Charles N ^a   Rocher, Leslie L ^a   Fisher, Gary J ^a   Baadsgaard, Ole ^a   Cooper, Kevin D ^a   Voorhees, John J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; CALCIUM ANTAGONIST; CARBAMAZEPINE; CEPHALOSPORIN; CORTICOSTEROID; CYCLOSPORIN; DANAZOL; DOXYCYCLINE; ERYTHROMYCIN; FUROSEMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; ISONIAZID; KETOCONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SULFINPYRAZONE; WARFARIN;

ARTICLE; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN DISEASE; SKIN MANIFESTATION; THERAPY; TOPICAL DRUG ADMINISTRATION;

EID: 0024949892     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(89)70339-X     Document Type: Article

References (152)

1. Metabolism of cyclosporine
2. Effects of the new anti-lymphocyte peptide cyclosporin A in animals
3. Cyclosporin A: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogenic bone marrow grafts
4. Immunopharmacologic monitoring of cyclosporin A treated recipients of cadaveric kidney allografts
5. Cyclosporine: pharmacokinetics, metabolism and drug interactions
6. Clinical pharmacokinetics of cyclosporin
7. Intravenous cyclosporine kinetics in renal failure
8. Comparison and correlation of assays for monitoring cyclosporine drug levels in renal transplant patients
9. Methods to measure cyclosporine levels—high-performance liquid chromatography, radioimmunoassay and correlation
10. Comparison of Abbott TDx fluorescence polarization immunoassay, Sandoz radioimmunoassay and high-performance liquid chromatography methods for the assay of serum cyclosporine
11. Cyclosporine A: a clinical evaluation of drug interactions
12. Cyclosporine drug interactions: a review
13. Confirmation of the interaction between cyclosporine and the calcium channel blacker nicardipine in renal transplant patients
14. Serious interaction between cyclosporine A and sulphadimidine
15. Action and toxicity of cyclosporine
16. The effects of cyclosporine A on the immune system
17. Mechanism of action of cyclosporin A in vivo
18. T-cell subpopulations in the blood and skin of patients with psoriasis
19. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis
20. Cyclosporine: a new immunosuppressive agent for organ transplantation
21. Psoriasic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells
22. Cyclosporine A inhibits antigen-presenting and accessory cell functions of Langerhans cells [Abstract]
23. Direct cytopathic effects of cyclosporine A on rapidly proliferating cultured keratinocytes and dermal fibroblasts
24. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum-free versus serum-containing media
25. Cyclophilin: a specific cytosolic binding protein for cyclosporine A
26. Cyclosporine A binding to calmodulin: a possible site of action on T lymphocytes
27. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporin
28. Cyclosporin A for psoriasis
29. Die Behandlung der Psoriasis-Arthritis mit Cyclosporin A, einem neuen Immunosuppressivum
30. Cyclosporine for psoriasis
31. Cyclosporine and psoriasis
32. Short-term use of cyclosporine A in severe psoriasis
33. Psoriasis
34. Cyclosporin treatment of severe psoriasis
35. Clearance of psoriasis with low dose eyclosporine
36. Clearance of psoriasis with low dose cyclosporin
37. Cutaneous lesions in 67 cyclosporin-treated renal transplant recipients
38. Cyclosporine in the treatment of psoriasis
39. Treatment of resistant severe psoriasis with systemic cyclosporine
40. Generalized pustular psoriasis (van Zumbusch) responding to cyclosporin A
41. Cyclosporine improves psoriasis in a double-blind study
42. Low-dose cyclosporin A in severe psoriasis. A double blind study
43. Cyclosporine A in the treatment of psoriatic arthritis
44. Cyclosporin A in acrodermatitis continua
45. In situ demonstration of T cells in alopecia areata
46. Traitement de pelades severes par applications locales de cyclosporine
47. Placebo-controlled trial of topical cyclosporin in severe alopecia areata
48. Topical cyclosporin in alopecia areata and nickel contact dermatitis
49. Traitement des pelades severes par applications locales de cyclosporine A
50. Topical cyclosporine in alopecia areata
51. Cyclosporin A-induced hair growth in human renal allograft recipients and alopecia areata
52. Cyclosporine A in the treatment of severe alopecia areata
53. Cyclosporine and male-pattern alopecia
54. Efficacy of low-dose cyclosporine in severe atopic skin disease
55. Epidermal activation of autoreactive T cells in atopic dermatitis: response to cyclosporine A
56. Topical cyelosporine inhibits contact sensitivity reactions to DNFB in the guinea pig
57. Cyclosporine and murine allergic contact dermatitis
58. Topical cyclosporin A in nickel contact hypersensitivity: results of a preliminary clinical and immunohistochemical investigation
59. Topical cyclosporin and psoriasis
60. Improvement of ichthyosis by cyclosporin
61. Cyclosporine A in lamellar ichthyosis
62. Effects of cyclosporine on bullous pemphigoid and pemphigus
63. Cyclosporine: new immunosuppressive agent in bullous pemphigoid and Pemphigus
64. Cyclosporin A in der Behandlung von Pemphigus Foliaccous and Pemphigus Erythematosus
65. La ciclosporine dans le traitement de la pemphigoide bulleuse: étude preliminaire
66. Bullous pemphigoid and response to cyclosporin
67. Pemphigus foliaceus and response to cyclosporin
68. Treatment of pemphigus with ciclosporin
69. Treatment of nine cases of pemphigus vulgaris with cyclosporine
70. Treatment of intraocular inflammatory disease with cyelosporin A
71. Cyclosporin in Behçet's disease
72. Cyclosporin in Behçet's disease
73. Effectiveness of cyclosporin therapy for Behget's disease
74. Cyclosporin A is effective, but not safe, in the management of Behçet's disease [Letter]
75. Treatment of epidermolysis bullosa acquisita with cyclosporin [Letter]
76. Cyclosporin A in epidermolysis bullosa acquisita
77. Clearing of epidermolysis bullosa acquisita with cyclosporine
78. Cyclosporin A is selectively cytotoxic to human leukemic T cells in vitro
79. Treatment of Sézary syndrome with cyclosporin. A
80. Treatment of cutaneous T cell lymphoma with cyclosporin A
81. Treatment of therapy-resistant Sézary syndrome with Cyclosporin-A: suppression of pruritus, leukaemic T cell activation markers and markers and tumour mass
82. Remission in skin infiltrate of a patient with mycosis fungoides treated with cyclosporine
83. Cyclosporin A therapy for mycosis fungoides
84. Cyclosporin A (cyclosporine) in the treatment of cutaneous T cell lymphoma (mycosis fungoides)
85. Extracutaneous spreading with fatal outcome of mycosis fungoides in a patient treated with ciclosporine A: a word of caution
86. Cyclosporine for juvenile dermatomyositis
87. Cyclosporin for polymyositis
88. Cyclosporin for polymyositis
89. Severe dermatomyositis treated with cyclosporin A
90. Cyclosporin for acute dermatomyositis
91. Cyclosporine in the treatment of intractable polymyositis
92. Cyclosporine treatment for intractable polymyositis
93. Combined ciclosporin-steroid treatment of systemic lupus erythematosus
94. Possible beneficial effect of ciclosporine in some cases of severe systemic lupus erythematosus
95. Open therapeutic trial of ciclosporin in systemic lupus erythematosus. Preliminary results in 4 patients
96. The effects of ciclosporin in twelve patients with severe lupus
97. Ciclosporin (CsA) and therapeutic plasma exchange in steroid resistant SLE
98. Cyclosporine in the treatment of lupus erythematosus
99. Persistent light reaction
100. Ciclosporin in the treatment of progressive systemic sclerosis
101. Cyclosporine in successful control of rapidly progressing scleroderma
102. Cyclosporin A in systemic sclerosis
103. Pyoderma gangrenosum treated with cyclosporin A
104. Pyoderma gangrenosum
105. Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangiitis and ulcerative colitis
106. Treatment of recalcitrant pyoderma gangrenosum with cyelosporine
107. Cyclosporin for pulmonary sarcoidosis
108. Ciclosporin (CyA) in the treatment of pulmonary sarcoidosis
109. Cyclosporine A in a case of refractory systemic and cutaneous sarcoidosis
110. Uveitis, cutaneous and neurosarcoid: treatment with low dose cyclosporine A
111. Effect of cyclosporine A in erythema nodosum leprosum
112. Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission
113. Side effects of systemic cyclosporine in patients not undergoing transplantation
114. Hyperkalemia in cyclosporin-treated renal allograft recipients
115. Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients
116. Assessment of the risks of malignancy and lymphomas developing in patients using Sandimmune
117. Malignancies following the use of cyclosporin A in man
118. Cancers following cyclosporine therapy
119. Cancers following cyclosporine therapy
120. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy
121. Rapid occurence of nodular cutaneous T-lymphocyte infiltrates with cyclosporine therapy
122. Complications of eyclosporin therapy
123. Cyclosporine: the agent and its actions
124. Infections in kidney, heart, and I iver transplant recipients on cyclosporine
125. Cyclosporin A hepatotoxicity in 66 renal allograft recipients
126. Experience with cyclosporine in cardiac transplantation
127. Cyclosporine immunosuppression
128. Cyclosporin A treatment of refractory rheumatoid arthritis
129. Clinical and pharmacy logic correlations in cyclosporine-induced gingival hyperplasia
130. Light and electron microscopic study of cyclosporin A—induced gingival hyperplasia
131. Complications of cyclosporine therapy—a comparison to azathioprine
132. Changes in facial appearance during cyclosporin treatment
133. Hypertrichosis in patients receiving cyclosporine therapy
134. Cyelosporin in cadaveric renal transplantation: one year followup of a multicentre trial
135. The presence of cyclosporine in body tissues and fluids during pregnancy
136. Renal function in a newborn baby delivered of a renal transplant patient taking cyclosporine
137. Successful pregnancy in a renal transplant patient taking cyclosporine A
138. Successful pregnancy after marrow transplantation for severe aplastic anemia and immunosuppression with cyclosporine
139. Anaphylactic reaction to intravenous cyclosporin
140. Anaphylactic reaction to intravenous cyclosporin
141. Absence of allergic reaction to cyclosporin capsules in patient allergic to standard oral and intravenous solution of cyclosporin
142. Anaphylactoid reactions associated with parenteral cyclosporine use: possible role for Cremophor El
143. Topical cyclosporine in psoriasis
144. Intralesional injection of cyclosporine in psoriasis